|
業務類別
|
Biotechnology |
|
業務概覽
|
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
| 公司地址
| 201 Elliott Avenue West, Seattle, WA, USA, 98119 |
| 電話號碼
| +1 206 676-5000 |
| 傳真號碼
| +1 206 676-5005 |
| 公司網頁
| https://www.omeros.com |
| 員工數量
| 202 |
| Dr. Gregory A. Demopulos,M.D. |
Chairman of the Board, President and Chief Executive Officer |
美元 960.95K |
30/05/2025 |
| Dr. George A. Gaitanaris, M.D.,PhD |
Vice President, Science and Chief Scientific Officer |
-- |
31/03/2025 |
| Dr. J. Whitaker, J.D.,M.D. |
Vice President, Clinical Development |
-- |
31/03/2025 |
| Mr. David J. Borges |
Vice President, Finance, Chief Accounting Officer, Principal Financial Officer and Treasurer |
美元 311.84K |
31/03/2025 |
| Mr. Peter W. Williams |
Vice President, Human Resources |
-- |
31/03/2025 |
| Mr. David W. Ghesquiere |
Vice President and Chief Business Development Officer |
-- |
31/03/2025 |
| Ms. Nadia Dac |
Vice President and Chief Commercial Officer |
-- |
31/03/2025 |
| Dr. Mariana N. Dimitrova, PhD |
Vice President, Chemistry, Manufacturing and Controls |
-- |
31/03/2025 |
| Mr. Peter B. Cancelmo |
Vice President, General Counsel and Corporate Secretary |
美元 483.65K |
31/03/2025 |
| Dr. Andreas Grauer, M.D. |
Vice President and Chief Medical Officer |
-- |
31/03/2025 |
| Dr. Catherine A. Melfi, PhD |
Vice President, Regulatory Affairs and Quality Systems and Chief Regulatory Officer |
-- |
31/03/2025 |
|
|
| Dr. Leroy E. Hood,M.D.,Ph. |
Independent Director |
30/05/2025 |
| Dr. Gregory A. Demopulos,M.D. |
Chairman of the Board, President and Chief Executive Officer |
30/05/2025 |
| Mr. Thomas J. Cable |
Lead Independent Director |
30/05/2025 |
| Dr. Peter A. Demopulos,M.D. |
Director |
30/05/2025 |
| Mr. Arnold C. Hanish |
Independent Director |
30/05/2025 |
| Dr. Thomas F. Bumol, PhD |
Independent Director |
30/05/2025 |
| Dr. Rajiv Shah, M.D. |
Independent Director |
30/05/2025 |
| Ms. Diana T. Perkinson |
Independent Director |
30/05/2025 |
|
|
|
|
